Read More

Genomics firm Twist Bioscience’s Momentum To Continue Throughout 2024, Analyst Says

Twist Bioscience reports strong Q2 earnings, with sales up 25% YoY to $75.3M and orders increasing by 45%. Gross margin expands to 41%. Fiscal year guidance was raised, and William Blair sees continued growth momentum. Analysts reaffirm Outperform ratings.

TWST

Read More

Stocks Rally As Jobs Report Rekindles Rate Cut Hopes, Apple Rockets, Bitcoin Soars Above $61,000: What’s Driving Markets Friday?

A weaker-than-expected jobs report sparked a widespread market rally in the last session of the week, as traders increased expectations on potential interest rate cuts later this year.

AMGN

Read More

Newly Listed Migraine-Focused AEON Biopharma Stock Plunges On Friday – Read Here Why

Preliminary results of AEON Biopharma's Phase 2 trial for chronic migraine treatment reveal no significant improvement over placebo. Despite anticipated reductions in monthly migraine days, statistical significance was not reached, prompting a review of development strategies and financial measures.

AEON